Spots Global Cancer Trial Database for Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors

Official Title: Arthralgia and Medication Adherence in Women With Early Stage Breast Cancer Taking Aromatase Inhibitors: The Breast Cancer Adjuvant Therapy (BCAT) Longitudinal Cohort Study.

Study ID: NCT00954564

Conditions

Arthralgia

Breast Cancer

Interventions

aromatase inhibition therapy - OBSERVATIONAL ONLY

medical chart review

questionnaire administration

assessment of therapy complications

Study Description

Brief Summary: RATIONALE: Gathering information over time about joint pain and stiffness from postmenopausal women with early-stage breast cancer who are receiving aromatase inhibitors may help doctors plan treatment and help patients live more comfortably. PURPOSE: This observational epidemiologic cohort is designed to study arthralgia, patient-reported outcomes, and medication adherence in postmenopausal women with early-stage breast cancer who are receiving aromatase inhibitors.

Detailed Description: OBJECTIVES: Primary * Estimate the incidence, time to onset, prevalence, and clinical and demographic predictors of arthralgia in post-menopausal women with early-stage breast cancer receiving aromatase inhibitors (AI). * Chart the trajectory of arthralgia symptom severity over the course of AI treatment in these patients. Secondary * Measure the impact of arthralgia on sleep quality, depression, and physical function in these patients. * Develop a roster of current physician-advised or prescribed treatments, including self-management techniques being used for AI-induced arthralgia, for intervention development. OUTLINE: Patients complete questionnaires about joint pain and stiffness, sleep, depression, physical function, medications and treatment, exercise and social support, demographics, comorbidities, body mass index (BMI), and performance status at baseline and then periodically for approximately 1 year after beginning aromatase inhibitor (AI) therapy. Patient medical records are reviewed for comorbidities, BMI, use of prior hormone replacement therapy, vitamin D levels and deficiency, performance status, histological stage, prior treatment, and medications at baseline and then periodically for approximately 1 year after beginning AI therapy.